Willeke Ros

3.2k citations

22 papers · 2.2k indexed · 3 hit papers · h-index 14

Oncology top 2%
Surgery top 5%
Immunology top 5%
Pulmonary and Respiratory Medicine top 5%
Epidemiology top 10%

Co-authors: Jan H.M. Schellens Jos H. Beijnen Sarina A. Piha‐Paul Hyun Cheol Chung Antoîne Italiano Jean‐Pierre Delord Scott K. Pruitt Neeltje Steeghs
Topics: Cancer Immunotherapy and Biomarkers (17 papers)CAR-T cell therapy research (10 papers)Monoclonal and Polyclonal Antibodies Research (10 papers)
Cited by: Oncology Obstetrics and Gynecology Immunology
Journals: Journal of Clinical Oncology Cancer Research Annals of Oncology
Partner nations: Netherlands United States France

In The Last Decade

Willeke Ros

21 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

2019 714 citations Hyun Cheol Chung, Willeke Ros et al. Journal of Clinical Oncology profile →
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

2019 404 citations Kimberley M. Heinhuis, Willeke Ros et al. Annals of Oncology profile →
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

2020 335 citations Sarina A. Piha‐Paul, Do‐Youn Oh et al. International Journal of Cancer profile →

Peers

Countries citing papers authored by Willeke Ros

Since Specialization

Citations

This map shows the geographic impact of Willeke Ros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willeke Ros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willeke Ros more than expected).

Fields of papers citing papers by Willeke Ros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willeke Ros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willeke Ros. The network helps show where Willeke Ros may publish in the future.

Co-authorship network of co-authors of Willeke Ros

This figure shows the co-authorship network connecting the top 25 collaborators of Willeke Ros. A scholar is included among the top collaborators of Willeke Ros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willeke Ros. Willeke Ros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors 2022 ·Journal for ImmunoTherapy of Cancer ·Omid Hamid,Alberto Chiappori,John A. Thompson,Toshihiko Doi,Siwen Hu‐Lieskovan,Ferry A.L.M. Eskens,Willeke Ros,Adi Diab,Jean‐Philippe Spano,Naiyer A. Rizvi,Jeffrey S. Wasser,Eric Angevin,Patrick A. Ott,Alison Forgie,Wenjing Yang,Cen Guo,Jeffrey Chou,Anthony B. El-Khoueiry	37
2	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studiesbreakdown → 2020 ·International Journal of Cancer ·Sarina A. Piha‐Paul,Do‐Youn Oh,Makoto Ueno,David Malka,Hyun Cheol Chung,Adnan Nagrial,Robin Kate Kelley,Willeke Ros,Antoîne Italiano,Kazuhiko Nakagawa,Hope S. Rugo,Filippo de Braud,Andréa Varga,Aaron R. Hansen,Hui Wang,Suba Krishnan,Kevin Norwood,Toshihiko Doi	335
3	P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort 2020 ·Poster presentations ·Alberto Chiappori,John A. Thompson,Fredericus Eskens,Jean‐Philippe Spano,Toshihiko Doi,Omid Hamid,Adi Diab,Naiyer A. Rizvi,Siwen Hu‐Lieskovan,Willeke Ros,Jacob Thomas,Alison Forgie,Wenjing Yang,(unknown),Ray Li,F Kazazi,Jeffrey Chou,(unknown)	11
4	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Studybreakdown → 2019 ·Journal of Clinical Oncology ·Hyun Cheol Chung,Willeke Ros,Jean‐Pierre Delord,Ruth Perets,Antoîne Italiano,Ronnie Shapira‐Frommer,(unknown),Sarina A. Piha‐Paul,Lei Xu,(unknown),Scott K. Pruitt,Alexandra Léary	714
5	Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumorsbreakdown → 2019 ·Annals of Oncology ·Kimberley M. Heinhuis,Willeke Ros,Marleen Kok,Neeltje Steeghs,Jos H. Beijnen,Jan H.M. Schellens	404
6	Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD‐1 Expression Levels and PD‐1 Receptor Occupancy by Nivolumab and Pembrolizumab 2019 ·Cytometry Part A ·Dick Pluim,Willeke Ros,(unknown),Jos H. Beijnen,Jan H.M. Schellens	13
7	Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid 2018 ·Journal of Pharmaceutical and Biomedical Analysis ·Dick Pluim,Willeke Ros,Mark T. J. van Bussel,Dieta Brandsma,Jos H. Beijnen,Jan H.M. Schellens	60
8	Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v) 2018 ·Annals of Oncology ·Ignacio Melero,(unknown),Morten Mau‐Sørensen,Ulrik Lassen,Martijn P. Lolkema,Debbie Robbrecht,Carlos Gomez‐Roca,Juan Martín-Liberal,Josep Tabernero,Willeke Ros,(unknown),Nicolás Isambert,(unknown),Christophe Boetsch,Jehad Charo,Stefan Evers,Volker Teichgräber,Jan H.M. Schellens	18
9	Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. 2018 ·Journal of Clinical Oncology ·Hyun Cheol Chung,José A. López-Martín,(unknown),Wilson H. Miller,Willeke Ros,Bo Gao,Aurélien Marabelle,Maya Gottfried,Alona Zer,Jean‐Pierre Delord,Nicolas Penel,Shadia I. Jalal,Lei Xu,(unknown),Scott K. Pruitt,Sarina A. Piha‐Paul	130
10	Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP). 2018 ·Journal of Clinical Oncology ·Morten Mau‐Sørensen,Willeke Ros,María E. Rodríguez-Ruiz,Debbie Robbrecht,Kristoffer Staal Rohrberg,Juan Martín-Liberal,Ulrik Lassen,Ignacio Melero,Martijn P. Lolkema,Josep Tabernero,Christophe Boetsch,(unknown),Inja Waldhauer,Jehad Charo,Stefan Evers,Volker Teichgräber,Jan H.M. Schellens	36
11	Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs) 2018 ·Annals of Oncology ·Omid Hamid,Siwen Hu‐Lieskovan,Willeke Ros,Adi Diab,Anthony B. El-Khoueiry,John A. Thompson,F. Eskens,(unknown),Eric Angevin,Naiyer A. Rizvi,Jeffrey S. Wasser,Patrick A. Ott,Alberto Chiappori,Tenshang Joh,Heike I. Krupka,Shobha Potluri,X. Wang,(unknown),Jeffrey Chou,Toshihiko Doi	2
12	Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb 2017 ·Annals of Oncology ·Omid Hamid,Willeke Ros,John A. Thompson,Siwen Hu‐Lieskovan,Fredericus Eskens,Adi Diab,Toshihiko Doi,Jeffrey S. Wasser,(unknown),Naiyer A. Rizvi,Eric Angevin,Alberto Chiappori,Patrick A. Ott,Bishu Ganguly,Catherine Fleener,(unknown),Kuo‐Wei Liao,Tenshang Joh,Jeffrey Chou,(unknown)	2
13	Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) 2017 ·Annals of Oncology ·Neil H. Segal,(unknown),Ignacio Melero,Willeke Ros,(unknown),Aurélien Marabelle,(unknown),Joan Albanell,Emiliano Calvo,Víctor Moreno,James M. Cleary,Joseph P. Eder,Vaios Karanikas,(unknown),Federico Sandoval,(unknown),Sasha Sreckovic,Herbert I. Hurwitz,L. Paz-Ares,Josep Tabernero	23
14	Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors 2017 ·Annals of Oncology ·Ignacio Melero,Neil H. Segal,(unknown),Willeke Ros,Maria Martinez‐García,(unknown),Víctor Moreno,Santiago Ponce,Aurélien Marabelle,James M. Cleary,Herbert I. Hurwitz,Joseph P. Eder,(unknown),Emilia Andersson,(unknown),Federico Sandoval,Marina Bacac,Tapan K. Nayak,Vaios Karanikas,Emiliano Calvo	2
15	The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600). 2017 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry,Omid Hamid,John A. Thompson,Willeke Ros,Ferry A.L.M. Eskens,Toshihiko Doi,Siwen Hu‐Lieskovan,Jeffrey Chou,(unknown),Bishu Ganguly,Catherine Fleener,Tenshang Joh,Adi Diab	14
16	Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors. 2017 ·Journal of Clinical Oncology ·Ignacio Melero,Neil H. Segal,(unknown),Willeke Ros,Maria Martinez‐García,Emiliano Calvo,Víctor Moreno,Santiago Ponce Aix,Aurélien Marabelle,James M. Cleary,Herbert I. Hurwitz,Joseph P. Eder,(unknown),Anton Belousov,(unknown),Federico Sandoval,Marina Bacac,Tapan K. Nayak,Vaios Karanikas,Guillem Argilés	1
17	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). 2017 ·Journal of Clinical Oncology ·Josep Tabernero,Ignacio Melero,Willeke Ros,Guillem Argilés,Aurélien Marabelle,María E. Rodríguez-Ruiz,Joan Albanell,Emiliano Calvo,Víctor Moreno,James M. Cleary,Joseph P. Eder,Vaios Karanikas,(unknown),Federico Sandoval,(unknown),Sasha Sreckovic,Herbert I. Hurwitz,Luis Paz‐Ares,(unknown),Neil H. Segal	128
18	A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies 2016 ·Annals of Oncology ·Adi Diab,Anthony B. El-Khoueiry,Ferry A.L.M. Eskens,Willeke Ros,John A. Thompson,Cyril Konto,(unknown),Tenshang Joh,Kuo‐Wei Liao,Bishu Ganguly,Omid Hamid	12
19	Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges 2016 ·The Oncologist ·Emilie M.J. van Brummelen,Willeke Ros,Gertjan Wolbink,Jos H. Beijnen,Jan H.M. Schellens	100
20	First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. 2016 ·Journal of Clinical Oncology ·Omid Hamid,John A. Thompson,Adi Diab,Willeke Ros,Ferry A.L.M. Eskens,(unknown),Cyril Konto,Hua Long,(unknown),Bishu Ganguly,Catherine Fleener,Susan Pleasic‐Williams,Pamela D. Garzone,Premal H. Patel,Tenshang Joh,Dimitry S.A. Nuyten,Anthony B. El-Khoueiry	22

About Willeke Ros

Willeke Ros is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 22 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). The work is most often cited by research in Oncology (1.6k citations), Obstetrics and Gynecology (232 citations) and Immunology (593 citations). Willeke Ros has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include Jan H.M. Schellens, Jos H. Beijnen, Sarina A. Piha‐Paul, Hyun Cheol Chung, Antoîne Italiano, Jean‐Pierre Delord, Scott K. Pruitt, Neeltje Steeghs, Marleen Kok and Kimberley M. Heinhuis. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact